EAGLE PHARMACEUTICALS, INC.

EGRX

Explore Our Financial Data > Companies > New Jersey Companies > EAGLE PHARMACEUTICALS, INC.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
EGRX
CIK0000827871
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE, NJ, 07677
Website eagleus.com
Phone201-326-5300
CEOScott L. Tarriff
Employees100

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$257.55 million
Pre-Tax Income$29.17 million
Net Income$11.95 million
Net Income to Common$11.95 million
EPS$0.89
View All
Balance Sheet
Cash$15.35 million
Assets$404.82 million
Liabilities$152.78 million
Common Equity$252.04 million
Liabilities & Equity$404.82 million
View All
Cash Flow Statement
Net Income$11.95 million
Cash From Operating Activities$-9.32 million
Cash From Investing Activities$-23.81 million
Cash From Financing Activities$11.92 million
Change in Cash$-21.21 million
View All
Calculations
NOPAT$16.80 million
EBITDA$56.80 million
Price to Earnings$2.33
Price to Book$0.11
ROE4.88%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares

On October 3, 2024, Union Square Park Capital Management, LLC (Trades, Portfolio) made a significant move in the pharmaceutical sector by acquiring 1,191,490 shares of Eagle Pharmaceuticals Inc (EGRX). This transaction marked a new holding for the firm, purchased at a price of $1.99 per share. The total investment impacted the firm's portfolio by 2.06%, establishing a substantial position in Eagle Pharmaceuticals.

Article Link

Top Midday Decliners

Top Midday Decliners

Article Link

Eagle Pharmaceuticals in Default Amid Delays in Financial Report Filings, Braces for Delisting

Eagle Pharmaceuticals in Default Amid Delays in Financial Report Filings, Braces for Delisting

Article Link

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10

Article Link

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on May 20, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it has initiated a process to delist the Company’s securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 (the “Q3 2023

Article Link